Primary Biliary Cirrhosis Treatment Market 2030 Competitive Study | Genfit, CymaBay, ZydusCadila, HighTide, Genkyotex, Cara Therapeutics etc

Primary Biliary Cirrhosis Treatment Market 2030 Competitive Study | Genfit, CymaBay, ZydusCadila, HighTide, Genkyotex, Cara Therapeutics etc

Primary Biliary Cirrhosis Treatment Market

DelveInsight’sPrimary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of Primary Biliary Cirrhosis Facts:

  • Prevalence of PBC was 33.8/100,000 in the Japanese population (Tanaka et al., 2019).
  • As per the study conducted by Yagi et al. (2018), in a cohort of PBC patients, the percentage comorbidities observed were 16% for Sjogren’s syndrome, 13% for chronic thyroiditis, and 7% for rheumatoid arthritis.
  • As per a study by Marzioni et al. (2018), the prevalence of PBC in Italy was 21.05/100,000.
  • According to Galoosian et al. (2020), Europe and North America have the highest reported prevalence of PBC worldwide, and the prevalence of PBC in females was 65.4/100,000 persons and 12.1/100,000 persons in males.
  • The prevalence of PBC increased by 30.9% (28/100,000 inhabitants in 2011 vs. 37/100,000 inhabitants in 2014).


Get more comprehensive insights into how Primary Biliary Cirrhosis epidemiological trends are impacting current and forecasted Primary Biliary Cirrhosis market @ Primary Biliary Cirrhosis Epidemiology Analysis and Forecast


Some of the Primary Biliary Cirrhosis Companies:

  • Genfit
  • CymaBay
  • ZydusCadila
  • HighTide
  • Genkyotex
  • Cara Therapeutics
  • And Many More


Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed. Bile is a fluid made in the liver. It aids with digestion and helps the body get rid of cholesterol, toxins, and worn-out red blood cells.

When the bile ducts are damaged, bile can back up in the liver and sometimes lead to irreversible scarring of liver tissue (cirrhosis). Other possible complications of PBC include an enlarged spleen, gallstones, high cholesterol levels, osteoporosis, and liver failure.

PBC has four stages. They are based on how much damage has been done to the liver. The stages include:

  • Stage 1: There are inflammation and damage to the walls of medium-sized bile ducts
  • Stage 2: There is blockage of the small bile ducts
  • Stage 3: This stage marks the beginning of scarring
  • Stage 4: Cirrhosis has developed. This is permanent, severe scarring and damage to the liver.


Request for Sample Copy:


Some of Primary Biliary Cirrhosis Report Highlight:

  • The report covers the descriptive overview of Primary Biliary Cirrhosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Primary Biliary Cirrhosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Primary Biliary Cirrhosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Primary Biliary Cirrhosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Biliary Cirrhosis market


Some of the Primary Biliary Cirrhosis Drugs:

  • Elafibranor
  • MBX-8025
  • Saroglitazar Mg
  • HTD 1801
  • GKT137831
  • CR845
  • And Many Others


Do you want to know how much market share the emerging therapies are going to capture by 2030? Contact @ Primary Biliary Cirrhosis Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the Primary Biliary Cirrhosis therapeutic outlook.


Table of Contents:

1. Key Insights

2. Executive Summary of Primary Biliary Cirrhosis

3. Competitive Intelligence Analysis for Primary Biliary Cirrhosis

4. Primary Biliary Cirrhosis: Market Overview at a Glance

4.1. Primary Biliary Cirrhosis Total Market Share (%) Distribution in 2017

4.2. Primary Biliary Cirrhosis Total Market Share (%) Distribution in 2030

5. Primary Biliary Cirrhosis: Disease Background and Overview

6. Patient Journey

7. Primary Biliary Cirrhosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Primary Biliary Cirrhosis Treatment

11. Marketed Products

12. Emerging Therapies

13. Primary Biliary Cirrhosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Biliary Cirrhosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Request for Sample Copy:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States